In vivo analysis shows that MSCs expressing CES1 and sTRAIL reduce tumor volume in lung cancer, implying potential for targeted therapy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: